I don't think it's a secret that Dr T is very optimistic for the future of Zantrene. He tempers his optimism here on HC with sage advice "do as I say not as I do" - but his excitement is obvious... and infectious.
Biotechs are a fascinating manner of speculative investment because due diligence is very much rewarded. Especially with Zantrene, we basically have a crystal ball in the historic literature. I'd go so far as to speculate that Daniel's background and experience in molecular biology and genomics actually give him a better vantage point than being a RAC insider.
Industry news, page-107
-
- There are more pages in this discussion • 1,712 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
